This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aim of this study is to determine the safety and tolerability of decitabine (5-aza-2'-deoxycytidine, Dacogen) when administered IV daily for 5 consecutive days prior to a single dose of IV dacarbazine (800 mg/M2) on day 8; to define all dose-limiting (grade III and IV) toxicities induced in patients receiving decitabine prior to dacarbazine.
Showing the most recent 10 out of 642 publications